Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice high of day close!
having a bit of trouble breaking past The mid $1.40 area but I think once the market gets back to "normal" we could see a move back up. Was trading at double this price not too long back.
Nice! Yea, looking good here.
I have a better average on recent buys that the insiders of this company. CEO bought at $3.01 not to long ago. This is a great entry point IMO. Welcome aboard.
SOURCE: Form 4
ISSUER: STEREOTAXIS INC
SYMBOL: STXS
FILER: MIDDLETON FRED A
TITLE: Chairman of the Board
DATE TRANSACTION SHARES PRICE VALUE
9/1/11 Purchase 17,119 $1.37 $23,453
OWNERSHIP: 314,905 (Direct) 4,525,658 (Indirect)
The Form 4 is filed with the Securities and Exchange Commission by insiders
to report transactions in their companies' shares. Open market purchases
and sales must be reported within two business days of the transaction.
Insider Data Source: The Washington Service
(info@washingtonservice.com or 301-913-5100)
(END) Dow Jones Newswires
09-06-11 1138ET
11:38 090611
Stereotaxis Inc. (STXS) CEO Michael P Kaminski buys 10,400 Shares
http://www.gurufocus.com/news/144583/stereotaxis-inc-stxs-ceo-michael-p-kaminski-buys-10400-shares
too greedy man ^^
Great flip again today. Reloaded in the 1.20s. Looking for 1.40 or better.
Bought in yesterday at 1.25 sold all at 1.50. Reloaded this morning at the open at 1.30. Looking good so far.
Why does the bid show 0.852??
Will be 5.00+ eoy imo
Yes indeed my friend!!
STXS patent portfolio. I did a search for Stereotaxis as the assignee (basically owner) of patents online at www.freepatentsonline.com (free search, but you have to register). The result was 283 issued patents and pending patent application, both US and worldwide. They seem to be on track for 25 issued patents and patent applications filed per year. Given that patent applications are not published until after 18 months after initial filing, good chance that there are at least another dozen or more filed in the last 18 months.
BOOOYYYAAAHHHH BABY!!!!!!
.
Was eyeing it all day yesterday and should've pulled the trigger. better late than never. I'll be happy with $2 for sure!
keep buying. Yesterday's news was pretty darn impressive. I know a little about tissue ablation having reviewed some patents on the matter with oncology applications. I need to do a patent search on stxs's IP next. They could be on to something.
to quote a friend of mine "running like a scalded dog! Run, bitch, run!" Meanwhile my support team of 2 terriers are at my feet. They are getting treats today! No scolding or scalding for them!
Just bought in.
I,M all :) today, this is just the start !!!
What are you considering near-term? 3-4 weeks?
$2.20 near term price target may need to be raised soon!!!!
.
VERY good news after hours today for sure. No doubt STXS is extremely oversold at this point and it appears the bottom reversal is taking place. UP UP UP WE GO!!!!
./
Stereotaxis’ STOP-VT Prospective Multicenter Study Results Featured at Europe’s Largest Medical Meeting, European Society of Cardiology
http://finance.yahoo.com/news/Stereotaxis-STOPVT-bw-1024000785.html?x=0&.v=1
Watch for the SUNH type move to take place here! Both are Waaaaaayyyyy oversold and are back on the way up!!!!
STXS will see $3.00 by eoy !!!! imo
.
Yeah, a lot of back and forth. Looks like folks flipping stuff earlier today that was bought in the low 1.00s an under from last few days, but beginning to consolidate. Not much volume relative to yesterday.
Looks like accumulation day today.
.
funny trading today
AND I'm Looking forward to much more to come!!!!
.
That probably explains the eod pop yesterday. This stuff always seems to leak. Definitely would welcome $2 soon!
NEWS today! ....Aug. 30, 2011, 7:27 a.m. EDT
The Board of Directors of Stereotaxis, Inc. (NASDAQ: STXS) announced today following its regularly scheduled board meeting that it reaffirmed the Company's plans for both the launch of the Epoch™ platform and expansion of the Odyssey™ platform into standard labs.
"At our meeting last week, the Board reviewed and endorsed the commercial strategies put forth for the launch of Epoch, as well as for the expansion of Odyssey's market penetration into standard labs," said Fred A. Middleton, Chairman of the Board of Directors. "We are encouraged by the positive early physician feedback to Epoch's productivity enhancements, and remain optimistic about the commercial potential for the Epoch magnetic surgery platform for robotic assisted surgeries in the cardiology suite. We are also encouraged by the positive trends in recurring revenue as reflected in our financial statements."
Mr. Middleton added, "The Board has established a Strategy Committee to evaluate various capital raising strategies to fund the Company's planned growth initiatives over the next 18 months, and we are focused on non-equity sources of funding as our first choice for raising capital since we believe our common stock is significantly undervalued in the public market."
The Company also completed last week its previously announced plans for operating expense reductions amounting to approximately 15 to 20% of annual operating expenses.
About Stereotaxis www.stereotaxis.com www.odysseyexperience.com
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Niobe® Remote Magnetic Navigation System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure.
Stereotaxis' Odyssey™ portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world. Odyssey™ Vision integrates data for magnetic and standard interventional labs, enhancing the physician workflow through a consolidated display of multiple systems and eliminating the challenge of interacting simultaneously with many separate diagnostic systems. Odyssey™ Enterprise Cinema then captures a complete record of synchronized procedure data that can be viewed live or from a comprehensive archive of cases performed. Odyssey™ then enables hospitals to efficiently share live and recorded clinical data anywhere around the world to maximize referrals and promote collaboration.
The core components of the Stereotaxis systems have received regulatory clearance in the U.S., Europe, Canada and elsewhere. For more information, please visit www.stereotaxis.com and www.odysseyexperience.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase our systems and the timing of such purchases, competitive factors, changes resulting from the recently enacted healthcare reform in the U.S., including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.
SOURCE Stereotaxis, Inc.
$2.00 BUCKS coming soon!!
.
Looks like good opportunity, especially with that recent insider purchase.
Still just the beginning here!!!
.
Looks like a little late afternoon action on this one.
Looks like the pps has settled after the big drop and we are now on the way up.
.
Looks like great potential here imo Tarheel.
.
eyeing this one LTM!
Looks like the bottom is in! UP UP UP WE GO!!!!
.
THe bottom I hope is now in,Hitting the low today of .88, It would be nice to see some green days.
Another today(8-22) @ .99, they dont seem to be buying alot though.
Followers
|
30
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
951
|
Created
|
03/01/11
|
Type
|
Free
|
Moderators |
http://www.stereotaxis.com/
Stereotaxis, Inc. is engaged in designing , manufacturing and marketing the Epoch Solution, which is an advanced remote robotic navigation system for use in a hospital's interventional surgical suite, or interventional lab. The Epoch Solution is consists of the Niobe ES Robotic Magnetic Navigation System (Niobe ES system), Odyssey Information Management Solution (Odyssey Solution), and the Vdrive Robotic Navigation System. The Company has alliances with Siemens, Philips and Biosense Webster. The Company has regulatory clearance, licensing and/or CE Mark approvals to market the Niobe Robotic Magnetic Navigation System, the Cardiodrive automated catheter advancement system, and various disposable interventional devices in the United States, Canada, Europe, China and various other countries.
Niobe ES Robotic Magnetic Navigation System
The Company’s Niobe ES robotic system provides the physician with remote digital instrument control through point and click computer mouse control, in combination with image integration and three dimensional (3D) reconstruction. It can be operated either from beside the patient table, as in traditional interventional procedures, or from a room adjacent to the patient and outside the x-ray fluoroscopy field. The Niobe ES robotic system allows the operator to navigate disposable interventional devices to the treatment site through paths in the blood vessels and chambers of the heart to deliver treatment by using computer controlled, externally applied magnetic fields to directly govern the motion of the working tip of these devices, each of which has a magnetically sensitive tip that predictably responds to magnetic fields generated by its system.
The Company has integrated its Niobe ES robotic system with Siemens’ and with Philips’ digital x-ray fluoroscopy systems. In addition, it have integrated the Niobe ES robotic system with Biosense Webster’s 3D catheter location sensing technology to provide real-time information as to the 3D location of the working tip of the instrument, and with Biosense Webster’s ablation tip technology. The components of the Niobe ES robotic system are Niobe Robotic Magnetic Navigation System, which utilizes two permanent magnets mounted on articulating and pivoting arms that are enclosed within a stationary housing, with one magnet on either side of the patient table. The Niobe ES robotic system is indicated for use in cardiac, peripheral and neurovascular applications and Cardiodrive Automated Catheter Advancement System, as the physician conducts the procedure from the adjacent control room, the Cardiodrive or QuikCAS automated catheter advancement systems are used to remotely advance and retract the electrophysiology catheter in the patient’s heart while the Niobe magnets steer the working tip of the device.
Odyssey Solution
The Odyssey Solution offers a fully integrated, real-time information solution to manage, control, record and share procedures across networks or around the world. Through the use of a single mouse and keyboard, the Odyssey Solution allows the user to command multiple systems in the lab from a single point of control. In addition, the Odyssey Solution acquires a real-time, remote view of the lab capturing synchronized procedure data for review of important events during cases. The Odyssey Solution enables physicians to access recorded cases and create snapshots following procedures for enhanced clinical reporting, auditing and presentation. The Odyssey Solution enables physicians to establish a master archive of procedures performed in the lab providing a tool for training new staff on the standard practices. The Odyssey Solution further enables procedures to be observed remotely around the world with Internet access over a hospital VPN even wirelessly using a standard laptop or Windows tablet computer.
Vdrive Robotic Navigation System
The Vdrive Robotic Navigation System and Niobe ES robotic system provide independent remote manipulation of diagnostic catheters and magnetic ablation catheters in a single interface. The Vdrive Robotic Navigation System provides navigation and stability for diagnostic and ablation devices designed with features to assist in the delivery of better ablations. Features include complementing the Niobe ES control of catheters for fully remote procedures; enabling fully remote, single operator workflow; and providing robotic control of diagnostic devices independent of magnetic navigation. The Vdrive Duo system is an optional expansion of the Vdrive hardware that allows control of the V-loop device and either V-CAS or V-CAS Deflect devices in the same procedure, with a single user interface.
Disposables and Other Accessories
The Company’s Niobe system is designed to use a toolkit of disposable interventional devices. The toolkit consists of Cardiodrive or QuikCAS, which is automated catheter advancement disposables designed to provide e remote advancement of electrophysiology catheters; Cronus, Assert, Titan and Pegasus coronary guidewires, which is designed for use in interventional cardiology procedures for the introduction and placement of over-the-wire therapeutic devices, such as stents and angioplasty balloons; and Biosense Webster’s CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL and CELSIUS RMT THERMOCOOL Irrigated Tip Diagnostic/Ablation Steerable Tip Catheters co-developed by Biosense Webster and Stereotaxis.
In addition to the Vdrive and Vdrive Duo systems, The Company also manufacture and market various disposable components, including V-CAS catheter advancement system that controls both the magnetic catheter body and a standard fixed-curve sheath; V-loop circular catheter manipulator, which allows the user to control certain circular mapping catheters, such as Biosense Webster’s LASSO2515 or LASSO2515 NAV Circular Mapping Catheter, and advance, retract, rotate, deflect and adjust loop radius, all without leaving the control room and V-CAS Deflect fully integrated catheter advancement system with a robotic deflectable sheath for
Contact Information |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |